Bone Fractures in Patients Using Tapentadol or Oxycodone: An Exploratory US Claims Database Study

References

• Centers for Disease Control and Prevention . U.S. opioid prescribing rate maps. (2020). www.cdc.gov/drugoverdose/maps/rxrate-maps.html
   Google Scholar
• O’Brien T , ChristrupLL , DrewesAMet.al European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur. J. Pain21(1), 3–19 (2017).
   PubMed Web of Science ®Google Scholar
• Dowell D , HaegerichTM , ChouR. CDC guideline for prescribing opioids for chronic pain – United States, 2016. JAMA315(15), 1624–1645 (2016).
   PubMed Web of Science ®Google Scholar
• Yue Q , MaY , TengYet.al An updated analysis of opioids increasing the risk of fractures. PLoS ONE15(4), e0220216 (2020).
   PubMed Web of Science ®Google Scholar
• Buckeridge D , HuangA , HanleyJet.al Risk of injury associated with opioid use in older adults. J. Am. Geriatr. Soc.58(9), 1664–1670 (2010).
   PubMed Web of Science ®Google Scholar
• Ensrud KE , BlackwellT , MangioneCMet.al Central nervous system active medications and risk for fractures in older women. Arch. Intern. Med.163(8), 949–957 (2003).
   PubMedGoogle Scholar
• Vestergaard P , RejnmarkL , MosekildeL. Fracture risk associated with the use of morphine and opiates. J. Intern. Med.260(1), 76–87 (2006).
   PubMed Web of Science ®Google Scholar
• Perez-Castrillon JL , OlmosJM , GomezJJet.al Expression of opioid receptors in osteoblast-like MG-63 cells and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. Neuroendocrinology72(3), 187–194 (2000).
   PubMed Web of Science ®Google Scholar
• Rosen H , Bar-ShavitZ. Dual role of osteoblastic proenkephalin derived peptides in skeletal tissues. J. Cell. Biochem.55(3), 334–339 (1994).
   PubMed Web of Science ®Google Scholar
• Rico H , CostalesC , CabranesJA , EscuderoM. Lower serum osteocalcin levels in pregnant drug users and their newborns at the time of delivery. Obstet. Gynecol.75(6), 998–1000 (1990).
   PubMed Web of Science ®Google Scholar
• Coluzzi F , PergolizziJ , RaffaRB , MattiaC. The unsolved case of “bone-impairing analgesics”: the endocrine effects of opioids on bone metabolism. Ther. Clin. Risk Manag.11, 515–525 (2015).
   PubMed Web of Science ®Google Scholar
• Saunders KW , DunnKM , MerrillJOet.al Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J. Gen. Intern. Med.25(4), 310–315 (2010).
   PubMed Web of Science ®Google Scholar
• Friedmann N , KlutzaritzV , WebsterL. Long-term safety of Remoxy® (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain. Pain Med.12(5), 755–760 (2011).
   PubMed Web of Science ®Google Scholar
• Gaskell H , DerryS , StannardC , MooreRA. Oxycodone for neuropathic pain in adults. Cochrane Database Syst. Rev.7, Cd010692 (2016).
   PubMedGoogle Scholar
• Cheung CW , ChingWong SS , QiuQ , WangX. Oral oxycodone for acute postoperative pain: a review of clinical trials. Pain Physician20(2s), Se33–se52 (2017).
   PubMedGoogle Scholar
• Schmidt-Hansen M , BennettMI , ArnoldS , BromhamN , HilgartJS. Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review. BMJ Support Palliat. Care8(2), 117–128 (2018).
   PubMed Web of Science ®Google Scholar
• Moradi M , EsmaeiliS , ShoarS , SafariS. Use of oxycodone in pain management. Anesth. Pain Med.1(4), 262–264 (2012).
   PubMedGoogle Scholar
• Yang PP , YehGC , YehTKet.al Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice. Pharmacol. Res.111, 867–876 (2016).
   PubMed Web of Science ®Google Scholar
• Schug SA . The atypical opioids: buprenorphine, tramadol and tapentadol. Medicine Today.19(Suppl. 9), 5–11 (2018).
   Google Scholar
• Tzschentke TM , JahnelU , KogelBet.al Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today (Barc.)45(7), 483–496 (2009).
   PubMed Web of Science ®Google Scholar
• Wade WE , SpruillWJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin. Ther.31(12), 2804–2818 (2009).
   PubMed Web of Science ®Google Scholar
• Afilalo M , EtropolskiMS , KuperwasserBet.al Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled Phase III study. Clin. Drug Investig.30(8), 489–505 (2010).
   PubMed Web of Science ®Google Scholar
• Hale M , UpmalisD , OkamotoA , LangeC , RauschkolbC. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr. Med. Res. Opin.25(5), 1095–1104 (2009).
   PubMed Web of Science ®Google Scholar
• Vorsanger G , XiangJ , OkamotoA , UpmalisD , MoskovitzB. Evaluation of study discontinuations with tapentadol inmmediate release and oxycodone immediate release in patients with low back or osteoarthritis pain. J. Opioid. Manag.6(3), 169–179 (2010).
   PubMedGoogle Scholar
• Buynak R , RappaportSA , RodKet.al Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial. Clin. Ther.37(11), 2420–2438 (2015).
   PubMed Web of Science ®Google Scholar
• Kavanagh S , KwongWJ , HammondGC , NelsonW , UpmalisD , YangM. Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain. Pain Med.13(9), 1110–1120 (2012).
   PubMed Web of Science ®Google Scholar
• Wild JE , GrondS , KuperwasserBet.al Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract.10(5), 416–427 (2010).
   PubMed Web of Science ®Google Scholar
• Baron R , JansenJP , BinderAet.al Tolerability, safety and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, Phase IIIb/IV trial. Pain Pract.16(5), 600–619 (2016).
   PubMed Web of Science ®Google Scholar
• Baron R , LikarR , Martin-MolaEet.al Effectiveness of tapentadol prolonged release (PR) compared with oxycodone/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, Phase IIIb/IV study. Pain Pract.16(5), 580–599 (2016).
   PubMed Web of Science ®Google Scholar
• Schwartz S , EtropolskiM , ShapiroDYet.al Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr. Med. Res. Opin.27(1), 151–162 (2011).
   PubMed Web of Science ®Google Scholar
• Haeseler G , SchaefersD , PrisonN , AhrensJ , LiuX , KarchA. Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone. BMC Anesthesiol.17(1), 91 (2017).
   PubMedGoogle Scholar
• Vorsanger GJ , KlopferAM , XiangJ , BensonCJ , MoskovitzBL , RosenthalNR. Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: a randomized, Phase IIIb study. J Opioid Manag.9(4), 281–290 (2013).
   PubMedGoogle Scholar
• Daniels SE , UpmalisD , OkamotoA , LangeC , HaeusslerJ. A randomized, double-blind, Phase III study comparing multiple doses of tapentadol IR, oxycodone IR and placebo for postoperative (bunionectomy) pain. Curr. Med. Res. Opin.25(3), 765–776 (2009).
   PubMed Web of Science ®Google Scholar
• Daniels S , CassonE , StegmannJUet.al A randomized, double-blind, placebo-controlled Phase III study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr. Med. Res. Opin.25(6), 1551–1561 (2009).
   PubMed Web of Science ®Google Scholar
• Imanaka K , TominagaY , EtropolskiMet.al Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr. Med. Res. Opin.29(10), 1399–1409 (2013).
   PubMed Web of Science ®Google Scholar
• Etropolski M , KellyK , OkamotoA , RauschkolbC. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Adv. Ther.28(5), 401–417 (2011).
   PubMed Web of Science ®Google Scholar
• Merchant S , ProvenzanoD , ModyS , HoKF , EtropolskiM. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies. J. Opioid Manag.9(1), 51–61 (2013).
   PubMedGoogle Scholar
• Hartrick C , Van HoveI , StegmannJU , OhC , UpmalisD. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, Phase III, randomized, double-blind, active- and placebo-controlled study. Clin. Ther.31(2), 260–271 (2009).
   PubMed Web of Science ®Google Scholar
• Biondi D , XiangJ , BensonC , EtropolskiM , MoskovitzB , RauschkolbC. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain. Pain Physician16(3), E237–246 (2013).
   PubMed Web of Science ®Google Scholar
• Etropolski M , LangeB , GoldbergJ , SteupA , RauschkolbC. A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain. J. Opioid Manag.9(5), 343–356 (2013).
   PubMedGoogle Scholar
• Lange B , KuperwasserB , OkamotoAet.al Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv. Ther.27(6), 381–399 (2010).
   PubMed Web of Science ®Google Scholar
• Riemsma R , ForbesC , HarkerJet.al Systematic review of tapentadol in chronic severe pain. Curr. Med. Res. Opin.27(10), 1907–1930 (2011).
   PubMed Web of Science ®Google Scholar
• Krebs EE , PaudelM , TaylorBCet.al Association of opioids with falls, fractures and physical performance among older men with persistent musculoskeletal pain. J. Gen. Intern. Med.31(5), 463–469 (2016).
   PubMed Web of Science ®Google Scholar
• Miller M , SturmerT , AzraelD , LevinR , SolomonDH. Opioid analgesics and the risk of fractures in older adults with arthritis. J. Am. Geriatr. Soc.59(3), 430–438 (2011).
   PubMed Web of Science ®Google Scholar
• Moura C , BernatskyS , AbrahamowiczMet.al Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporos. Int.25(5), 1473–1481 (2014).
   PubMed Web of Science ®Google Scholar
• Shen C , ChenF , ZhangY , GuoY , DingM. Association between use of antiepileptic drugs and fracture risk: a systematic review and meta-analysis. Bone64, 246–253 (2014).
   PubMed Web of Science ®Google Scholar
• Thong BKS , Ima-NirwanaS , ChinKY. Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. Int. J. Environ. Res. Public Health.16(9), 1571 (2019).
   PubMed Web of Science ®Google Scholar
• Tseng OL , SpinelliJJ , GotayCC , HoWY , McBrideML , DawesMG. Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis. Ther. Adv. Musculoskelet. Dis.10(4), 71–90 (2018).
   PubMed Web of Science ®Google Scholar
• van Staa TP , LeufkensHG , AbenhaimL , ZhangB , CooperC. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford.)39(12), 1383–1389 (2000).
   PubMed Web of Science ®Google Scholar
• Wallander M , AxelssonKF , LundhD , LorentzonM. Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO). Osteoporos. Int.30(1), 115–125 (2019).
   PubMed Web of Science ®Google Scholar
• Zhu ZN , JiangYF , DingT. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone68, 115–123 (2014).
   PubMed Web of Science ®Google Scholar
• Heikkila K , PearceJ , MakiM , KaukinenK. Celiac disease and bone fractures: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab.100(1), 25–34 (2015).
   PubMed Web of Science ®Google Scholar
• Poiana C , CapatinaC. Fracture risk assessment in patients with diabetes mellitus. J. Clin. Densitom.20(3), 432–443 (2017).
   PubMed Web of Science ®Google Scholar
• Schuit SC , vander Klift M , WeelAEet.al Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone34(1), 195–202 (2004).
   PubMed Web of Science ®Google Scholar
• Shirazi KM , SomiMH , RezaeifarP , FattahiI , KhoshbatenM , AhmadzadehM. Bone density and bone metabolism in patients with inflammatory bowel disease. Saudi J. Gastroenterol.18(4), 241–247 (2012).
   PubMed Web of Science ®Google Scholar
• Wu Q , LiuJ , Gallegos-OrozcoJF , HentzJG. Depression, fracture risk and bone loss: a meta-analysis of cohort studies. Osteoporos. Int.21(10), 1627–1635 (2010).
   PubMed Web of Science ®Google Scholar